Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
Study efficacy measures will include the expression of dystrophin protein and motor function.
New subgroup analysis from Phase III ARASENS trial shows that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel increased overall survival (OS)
Latest innovations feature vendor-neutral solutions to help reduce clinical complexity and enhance operational efficiency
The combination of Optym, Emmes' ophthalmology certification unit, and Clinical Edge will make the organization a leader in ophthalmic certification and training services
In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials
Gilman will be responsible for all business development and portfolio strategy efforts globally.
Subscribe To Our Newsletter & Stay Updated
